Trial Profile

An International Randomized Double-blind Clinical Trial of BCD-100 Plus Platinum-based Chemotherapy With and Without Bevacizumab Versus Placebo Plus Platinum-based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prolgolimab (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Paclitaxel
Indications Cervical cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms FERMATA
Sponsors Biocad

16 Feb 2024 This trial has been discontinued in Finland and Czech Republic, according to European Clinical Trials Database record.
13 Jun 2022 According to a Biocad media release, At least $20 million will be invested in DOMAJOR and FERMATA studies.
18 Dec 2020 This trial has been discontinued in Austria according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com